Search
Close this search box.
Search
Close this search box.

Press Releases

LeddarTech Showcases LeddarVision at AutoSens Europe: AI-Driven Innovation Enhanced With TI Processors and Arm Collaboration

A leap forward in automotive safety with LeddarTech and Arm QUEBEC CITY, Canada, Oct. 03, 2024 (GLOBE NEWSWIRE) — LeddarTech® Holdings Inc. (“LeddarTech”) (Nasdaq: LDTC), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology, LeddarVision™, for ADAS, AD and parking applications, proudly highlights

LeddarTech présente LeddarVision à AutoSens Europe : une innovation pilotée par l’IA, optimisée par les processeurs Texas Instruments et une collaboration avec Arm

A leap forward in automotive safety with LeddarTech and Arm QUÉBEC, Canada, 03 oct. 2024 (GLOBE NEWSWIRE) — LeddarTech® Holdings Inc. (« LeddarTech ») (NASDAQ : LDTC), une société de logiciels automobiles qui fournit des technologies logicielles de fusion bas niveau de capteurs et de perception reposant sur l’IA, innovatrices

Duck Creek Technologies inaugure un facilitateur de paiement permettant de créer une solution de bout en bout pour les paiements d’assurance

La nouvelle solution simplifie les paiements des assureurs tout en permettant des transactions sécurisées sur la plateforme éprouvée Duck Creek BOSTON, 02 oct. 2024 (GLOBE NEWSWIRE) — Duck Creek Technologies, le fournisseur de solutions intelligentes qui dessine les contours du secteur de l’assurance générale et IARD (incendies et risques divers),

Duck Creek Technologies Launches Payments Facilitator to Create End-To-End Insurance Payment Solution

New Solution Simplifies Insurance Carriers’ Payments Delivering Secure Transaction Capabilities as Part of the Proven Duck Creek Platform BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) — Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, today introduced its latest insurance-focused payments solution,

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphoma